← All posts

Hordeolum (Stye): Diagnosis, Management & Referral Guidelines

Uniqcret doctor knowledgesEyesINMED
On this page

✅ Diagnosis Criteria

A clinical diagnosis based on history and physical examination.

🔍 Diagnostic Features:

FeatureDescription
OnsetAcute (hours to 1–2 days)
LocationEyelid margin (external) or deeper in lid (internal)
PainPresent (distinguishes from chalazion)
TendernessLocalized; palpable nodule
SwellingFocal edema of eyelid (may progress to diffuse swelling)
ErythemaPresent, often localized to lesion
DischargeMay occur, especially in external hordeolum (purulent)
Systemic signsRare; consider if preseptal cellulitis develops

📊 Types:


🧠 Differential Diagnosis

ConditionKey Differences
ChalazionChronic, painless, noninfectious; granulomatous
Preseptal cellulitisDiffuse eyelid swelling, +/- fever, no focal nodule
DacryocystitisInfection of lacrimal sac, often medial lower eyelid
Sebaceous carcinomaSuspect in nonresolving, recurrent nodules in elderly


⏱️ Follow-up & Ophthalmology Referral

🗓️ Routine Follow-up:

👁️ Refer to Ophthalmology if:


🧾 Management

🩹 First-line (Conservative/Supportive):

💊 Topical Antibiotics (if infection suspected or recurrent):

Not necessary in all uncomplicated cases; reserve for purulence, blepharitis, or conjunctivitis.

💊 Oral Antibiotics (only for complicated cases):

Indications:

DrugDose
Cephalexin500 mg PO every 6 hours for 7 days
Dicloxacillin250–500 mg PO qid for 7 days
MRSA riskClindamycin or TMP-SMX

🛠️ Surgical Management:


⚠️ Prevention & Patient Education


📌 Summary Table

TreatmentIndication
Warm compressesFirst-line for all cases
Topical antibioticsRecurrent, purulent, or blepharitis
Oral antibioticsInternal, cellulitis, immunocomp.
Surgical drainageNon-resolving or large internal lesion
Refer ophthalmologyPersistent 2 wk, recurrent, or complicated
0
Message for International and Thai ReadersUnderstanding My Medical Context in ThailandRead more →Message for International and Thai ReadersUnderstanding My Broader Content Beyond MedicineRead more →

Comments

No comments yet. Be the first to share your thoughts.

Sign in to comment